New Delhi. India is gearing up for a large-scale COVID vaccination program, while health experts said on Sunday that the ideal difference between the first and second booster doses is considered to be 21 days. In addition, vaccinated people are required to maintain health hygiene, as they must be vaccinated over a specified period of time.
Do not worry about the side effects of the vaccine, headaches, body aches and high fever can occur within 48 hours of vaccination.
There will be a gap of 21 and 28 days –
Speaking of the Pfizer vaccine, a 21-day interval between two doses has been suggested and for the AstraZeneca vaccine a 28-day interval has been suggested. In addition, proper care, adequate rest, and precautions are suggested during this time to avoid infection. “Although a particular precautionary measure, such as staying at home, is not indicated, comprehensive care is recommended. The vaccine requires a 21-day interval between two doses and is generally protective in effectiveness seven days after the second dose. . Therefore, it is important that patients take precautions after the first dose of the vaccine. “
Expert warning: do not give alcohol more than two months after the Corona vaccine
The first 300 million people will be vaccinated –
Union Ministry of Health Secretary Rajesh Bhushan said 30 million people have been listed in priority population groups, including one million health workers, two million police department employees , armed forces, home guards, civil security organizations and 27 million people who are over 50 and under 50 but have other diseases The government should manufacture its first vaccine in the next few years weeks with around three candidates under active review by India’s drug regulator. The Union Health Ministry had said that around 1.54 lakh vaccines or auxiliary nurse midwives would be arranged for the introduction of the Kovid-19 vaccine as part of the universal vaccination program at the start of the vaccination process. .
Work in progress on these vaccines –
There are eight candidate vaccines, which may be ready for authorization in the near future. These include AstraZeneca and the Covishield Serum Institute of India, developed and produced by the University of Oxford, Kovaxin from Bharat Biotech Ltd., Zaikov-D from Zydus Cadila, Russian vaccine candidate Sputnik-5, NVI -Cove 2373 from SII, HGCO 19 from Geneva and two unlabelled vaccines. , Which comprises the recombinant protein antigen vaccine from Biological E Ltd and the inactive rabies vector from Bharat Biotech. The Pune-based Serum Institute of India and Hyderabad-based pharmaceutical company Bharat Biotech have already applied to the Drugs Controller General of India (DCGI). They are seeking emergency use authorization for a potential COVID-19 vaccine.